GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Investments And Advances

ValiRx (LSE:VAL) Investments And Advances : £0.00 Mil (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Investments And Advances?

ValiRx's Investments And Advances for the quarter that ended in Jun. 2023 was £0.00 Mil.


ValiRx Investments And Advances Historical Data

The historical data trend for ValiRx's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Investments And Advances Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ValiRx Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


ValiRx (LSE:VAL) Business Description

Industry
Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.

ValiRx (LSE:VAL) Headlines

From GuruFocus

Valaris Reports Second Quarter 2023 Results

By Business Wire 08-02-2023

Valaris Announces Contract Awards and Fleet Status Updates

By Business Wire Business Wire 12-16-2022

Valaris Provides Fleet Status Report

By Business Wire Business Wire 05-02-2023

Valaris Provides Quarterly Fleet Status Report

By Business Wire Business Wire 10-31-2022

Valaris to Present at Fearnley Securities' Offshore Drilling Seminar

By Business Wire Business Wire 01-10-2023

Valaris to Present at the BofA Securities Global Energy Conference

By Business Wire Business Wire 11-14-2022